thalidomide has been researched along with Breathlessness in 17 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 8.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 8.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 7.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 6.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "POEMS syndrome is associated with plasma cell dyscrasias and upregulation of vascular endothelial growth factor leading to systemic oedema, papilloedema and pulmonary hypertension." | 5.48 | POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation. ( Gilbert, L; Ordway, S; Wanko, S, 2018) |
| "We conclude that the combination of thalidomide plus dexamethasone is a feasible and active regimen in the treatment of multiple myeloma." | 5.10 | Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, S; Greipp, PR; Hayman, S; Iturria, N; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2002) |
| " There was weak evidence for the improvement of 6MWD using oxygen; dyspnoea using prednisolone, diamorphine, D-pencillamine and colchicine; cough using interferon α and thalidomide; anxiety using diamorphine; fatigue using pulmonary rehabilitation; and QoL using thalidomide and doxycycline." | 4.89 | Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. ( Bajwah, S; Higginson, IJ; Koffman, J; Patel, AS; Peacock, JL; Riley, J; Ross, JR; Wells, AU, 2013) |
| "Lenalidomide is a potent, novel thalidomide analog that has demonstrated promising clinical activity in patients with relapsed or refractory multiple myeloma (MM)." | 4.84 | Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma. ( Tariman, JD, 2007) |
| "To detail the dyspnea encountered in women receiving thalidomide as therapy for advanced ovarian cancer." | 4.82 | Dyspnea during thalidomide treatment for advanced ovarian cancer. ( Dizon, DS; Gordinier, ME, 2005) |
| "Lenalidomide is a derivative of thalidomide and is FDA-approved for the treatment of myelodysplastic syndrome and, in combination with dexamethasone, for the treatment of relapsed multiple myeloma." | 3.78 | Reversible pulmonary toxicity due to lenalidomide. ( Barker, A; Coates, S; Spurgeon, S, 2012) |
| "Lenalidomide is an immunomodulatory agent approved for use in patients with myelodysplastic syndrome, and in combination with dexamethasone for refractory or relapsed multiple myeloma." | 3.74 | Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. ( Abonour, R; Knox, K; Smith, P; Thornburg, A; Twigg, HL, 2007) |
| "The myelodysplastic syndromes are a heterogeneous group of clonal diseases of haemopoiesis, which are a challenge for both biologists and clinicians." | 2.41 | Thalidomide in myelodysplastic syndromes. ( Pozzato, G; Zorat, F, 2002) |
| "POEMS syndrome is associated with plasma cell dyscrasias and upregulation of vascular endothelial growth factor leading to systemic oedema, papilloedema and pulmonary hypertension." | 1.48 | POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation. ( Gilbert, L; Ordway, S; Wanko, S, 2018) |
| "Laboratory tests objectified severe renal failure with creatinine level 107mg, urea 1." | 1.48 | [Renal failure revealing multiple myeloma with preexisting lesions on radiological images]. ( Bouchemla, N; Chettati, M; Fadili, W; Laouad, I; Nadri, A, 2018) |
| " We conclude that severe lung toxicity should be included among the potential adverse effects of thalidomide." | 1.31 | [Lung toxicity due to thalidomide]. ( Bertomeu González, V; Carrión Valero, F, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Comba, IY | 1 |
| Chahin, A | 1 |
| Taj, H | 1 |
| Carilli, A | 1 |
| Li, Y | 1 |
| Ren, XY | 1 |
| Sun, F | 1 |
| Wang, P | 1 |
| Zhao, JL | 1 |
| Wu, QJ | 1 |
| Zeng, XF | 1 |
| Ordway, S | 1 |
| Gilbert, L | 1 |
| Wanko, S | 1 |
| Bouchemla, N | 1 |
| Nadri, A | 1 |
| Chettati, M | 1 |
| Fadili, W | 1 |
| Laouad, I | 1 |
| Merz, M | 1 |
| Herth, I | 1 |
| Brandt, J | 1 |
| Hundemer, M | 1 |
| Neben, K | 1 |
| Goldschmidt, H | 1 |
| Heußel, CP | 1 |
| Coates, S | 1 |
| Barker, A | 1 |
| Spurgeon, S | 1 |
| Benjamin, M | 1 |
| Gibbs, S | 1 |
| Bajwah, S | 1 |
| Ross, JR | 1 |
| Peacock, JL | 1 |
| Higginson, IJ | 1 |
| Wells, AU | 1 |
| Patel, AS | 1 |
| Koffman, J | 1 |
| Riley, J | 1 |
| Carrión Valero, F | 2 |
| Bertomeu González, V | 1 |
| Rajkumar, SV | 1 |
| Hayman, S | 1 |
| Gertz, MA | 1 |
| Dispenzieri, A | 1 |
| Lacy, MQ | 1 |
| Greipp, PR | 1 |
| Geyer, S | 1 |
| Iturria, N | 1 |
| Fonseca, R | 1 |
| Lust, JA | 1 |
| Kyle, RA | 1 |
| Witzig, TE | 1 |
| Rechner, I | 1 |
| Brito-Babapulle, F | 1 |
| Fielden, J | 1 |
| Díaz García, B | 1 |
| de Pablo Gafas, A | 1 |
| Ferreiro Alvarez, MJ | 1 |
| Gordinier, ME | 1 |
| Dizon, DS | 1 |
| Thornburg, A | 1 |
| Abonour, R | 1 |
| Smith, P | 1 |
| Knox, K | 1 |
| Twigg, HL | 1 |
| Tariman, JD | 1 |
| Zorat, F | 1 |
| Pozzato, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcad[NCT00443235] | Phase 3 | 260 participants (Anticipated) | Interventional | 2005-03-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for thalidomide and Breathlessness
| Article | Year |
|---|---|
Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colchicine; Cough; Dyspnea; Exercise | 2013 |
Dyspnea during thalidomide treatment for advanced ovarian cancer.
Topics: Adult; Aged; Dyspnea; Female; Humans; Immunosuppressive Agents; Middle Aged; Neoplasm Recurrence, Lo | 2005 |
Lenalidomide: a new agent for patients with relapsed or refractory multiple myeloma.
Topics: Anorexia; Antineoplastic Agents; Apoptosis; Constipation; Diarrhea; Drug Eruptions; Drug Monitoring; | 2007 |
Thalidomide in myelodysplastic syndromes.
Topics: Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Chromosome Abe | 2002 |
1 trial available for thalidomide and Breathlessness
| Article | Year |
|---|---|
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Constipation; Dexamethasone; Dyspnea; E | 2002 |
12 other studies available for thalidomide and Breathlessness
| Article | Year |
|---|---|
Pomalidomide and dexamethasone in myelomatous pleural effusion.
Topics: Dexamethasone; Drainage; Dyspnea; Humans; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Pleural | 2020 |
[The 456th case: polyarthritis, dry cough, dyspnea on exertion].
Topics: Arthralgia; Arthritis, Rheumatoid; Autoantibodies; Blood Sedimentation; C-Reactive Protein; Cough; D | 2017 |
POEMS syndrome: diagnostic delay and successful treatment with lenalidomide, cyclophosphamide and prednisone followed by autologous peripheral stem cell transplantation.
Topics: Adult; Combined Modality Therapy; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, Combinati | 2018 |
[Renal failure revealing multiple myeloma with preexisting lesions on radiological images].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cyclophosphamide; Dexamethasone; Dyspnea | 2018 |
[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].
Topics: Acute Disease; Aged; Comorbidity; Dexamethasone; Dyspnea; Hematopoietic Stem Cell Transplantation; H | 2014 |
Reversible pulmonary toxicity due to lenalidomide.
Topics: Antineoplastic Agents; Cough; Dyspnea; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Th | 2012 |
Amyloidosis.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Boronic | 2011 |
[Lung toxicity due to thalidomide].
Topics: Aged; Cough; Dyspnea; Follow-Up Studies; Humans; Immunosuppressive Agents; Lung; Male; Multiple Myel | 2002 |
Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Combined Modality Th | 2003 |
[Lung toxicity due to thalidomide].
Topics: Cough; Dyspnea; Humans; Immunosuppressive Agents; Lung; Lung Diseases; Multiple Myeloma; Radiography | 2003 |
[Lung toxicity due to thalidomide].
Topics: Dyspnea; Humans; Immunosuppressive Agents; Lung; Lung Diseases; Thalidomide | 2003 |
Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Dys | 2007 |